Evidence has indicated that Il-1β may play a beneficial role in limiting AD pathology, and sustained overexpression of Il-1β reduces Aβ-related pathology by modulating microglia-dependent plaque degradation or promoting non-amyloidogenic APP cleavage in an AD mouse model and in cell culture62–64. This evidence concerns the gene IL1B and Alzheimer disease.